Investment Thesis
VIEMED demonstrates solid 20.5% YoY revenue growth, but fundamentals are challenged by thin operating margins (5.7%), weak return on equity (1.8%), and severely constrained free cash flow generation (1.8% FCF margin). The capital-intensive business model and low profitability metrics suggest limited financial flexibility despite a healthy balance sheet.
Strengths
- Strong revenue growth at 20.5% YoY indicates solid market demand
- Excellent balance sheet with minimal leverage (0.06x Debt/Equity) and adequate liquidity (1.22x current ratio)
- Healthy gross margin of 56.8% demonstrates reasonable unit economics and pricing power
Risks
- Severely compressed profitability: operating margin of 5.7% and net margin of 3.4% indicate structural margin pressure
- Extremely poor capital efficiency: ROE of 1.8% and ROA of 1.3% show inadequate returns on the 197.4M asset base
- Weak cash generation relative to capital intensity: FCF of 1.4M (1.8% margin) against 6.7M capex limits financial flexibility
- Cash position of 9.8M is minimal relative to revenue scale, leaving limited cushion for operational challenges
Key Metrics to Watch
- Operating margin expansion - critical to assess if growth translates to profitability
- Free cash flow generation and FCF conversion ratio - essential for debt reduction and reinvestment capacity
- Return on equity and return on assets trends - current 1.8% ROE and 1.3% ROA are unsustainably low
Financial Metrics
Revenue
75.4M
Net Income
2.6M
EPS (Diluted)
$0.06
Free Cash Flow
1.4M
Total Assets
197.4M
Cash
9.8M
Profitability Ratios
Gross Margin
56.8%
Operating Margin
5.7%
Net Margin
3.4%
ROE
1.8%
ROA
1.3%
FCF Margin
1.8%
Balance Sheet & Liquidity
Current Ratio
1.22x
Quick Ratio
1.10x
Debt/Equity
0.06x
Debt/Assets
26.1%
Interest Coverage
N/A
Long-term Debt
8.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:58:18.456376 |
Data as of: 2026-03-31 |
Powered by Claude AI